Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Ocular And UroGen Team-Up With Drug-Makers On Drug-Delivery Hydrogels

Executive Summary

Ocular Therapeutix will work with Regeneron to create a sustained-release formulation of aflibercept for the treatment of wet age-related macular degeneration and other serious retinal diseases. On the same day, UroGen announced plans to work with Allergan on a hydrogel for controlled release delivery of drugs to the bladder.

Advertisement

Related Content

After Tocagen Thaws IPO Freeze, Verona And Zymeworks Bring April Total To Three
Regeneron Partnering With Ocular May Provide Needed Tech Validation
Botox Adds Therapeutic Indication For Idiopathic Overactive Bladder

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT103969

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel